M.D. Anderson Cancer Center
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Primary Objectives * To assess the rate of MMR by 12 months. Secondary Objectives * To assess the rate of CCyR by 12 months. * To estimate the proportion of participants with 4.5-log reduction of BCR::ABL1 transcripts (MR4.5) at 6, 12, 18, 24, and 36 months of therapy. * To estimate the rate of sustained deep molecular response. * To estimate event-free survival and overall survival. * To assess the toxicity of olverembatinib monotherapy. * To assess health-related quality of life (HRQOL) of the participants.
Eligibility Criteria: * Adult participants age ≥18 years. * Participants must have a diagnosis of Ph-positive or BCR::ABL1 positive CML in early chronic phase. * Participants who received prior hydroxyurea, 1 to 2 doses of cytarabine, and/or an FDA approved TKI for ≤ 30 days are eligible. * Participants with additional chromosomal abnormalities at diagnosis (early disease) and no other criteria for accelerated phase will be eligible for this study. * ECOG performance status ≤ 2. * Participants must have adequate end organ function, defined as the following: total bilirubin ≤1.5x ULN (unless s…
GIven by PO
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.